Monitoring kidney transplant rejection using blood tests

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the relationship between donor-derived cell-free DNA (DD-cfDNA) levels and HLA antibodies in the blood of kidney transplant recipients. It seeks to improve the detection of kidney transplant rejection by utilizing the Molecular Microscope® Diagnostic System (MMDx) alongside the Prospera® test, which quantifies DD-cfDNA through advanced sequencing techniques. The study will involve kidney transplant patients who are undergoing biopsies for clinical reasons, allowing for a comprehensive assessment of rejection and injury. By comparing traditional methods with molecular diagnostics, the study hopes to enhance the accuracy of rejection detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.

Exclusion Criteria:

* Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.

Where it's running

• Tampa General Hospital
  Tampa, Florida, United States Recruiting
• University of Maryland School of Medicine
  Baltimore, Maryland, United States Recruiting
• The Johns Hopkins University, School of Medicine
  Baltimore, Maryland, United States Recruiting
• Henry Ford Hospital
  Detroit, Michigan, United States Recruiting
• Barnes-Jewish Hospital, Washington University at St. Louis
  St Louis, Missouri, United States Recruiting
• University Hospitals Cleveland Medical Ctr.
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Philip F Halloran, MD, PhD — University of Alberta
• Study coordinator: Konrad S Famulski, PhD
• Email: konrad@ualberta.ca
• Phone: 1 780 492 1725

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belimumab to mobilize memory B cells to help delistings for highly sensitized kidney transplant candidates

  A short belimumab course is being tested to see if it can reveal memory B cells that target donor HLAs, helping to decide which donors to exclude and potentially speed up getting a transplant for highly sensitized patients.

  Recruiting Phase 2 Leiden University Medical Center · Leiden · NCT07539857

• Frexalimab versus tacrolimus to prevent kidney transplant rejection

  This trial will test whether frexalimab injections given for up to five years work as well and are as safe as tacrolimus capsules at preventing rejection in adults getting their first kidney transplant who have low-to-moderate immune risk.

  Recruiting at 73 sites Phase 2/3 Sanofi · San Francisco, California and 72 other locations · NCT07412470

• Platelet aggregation for diagnosing acute kidney transplant rejection

  This study will test whether changes in platelet activation measured from blood can help detect acute rejection in adult kidney transplant recipients.

  Recruiting University Hospital, Martin · Martin · NCT07275541

• Donor-Derived Cell-Free DNA Test for Monitoring Kidney Transplants

  This test will try whether a blood-based donor-derived cell-free DNA (dd-cfDNA) assay can detect rejection in adults who have received a kidney transplant.

  Recruiting at 6 sites Insight Molecular Diagnostics · Los Angeles, California and 9 other locations · NCT07060716

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

• Tocilizumab plus standard therapy for chronic antibody-mediated rejection after kidney transplant

  This trial will try adding tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) to see if it helps people with chronic active antibody-mediated rejection of a kidney transplant.

  Recruiting Shahid Beheshti University of Medical Sciences · Tehran · NCT07006532

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.